Hosted on MSN
ABT Q1 Deep Dive: Growth in Devices, Product Pipeline, and Tariff Mitigation Shape Outlook
Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2025, with sales up 7.4% year on year to $11.14 billion. Its non-GAAP profit of $1.26 per share was in line with analysts’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback